Production Assistance for Cellular Therapies PACT

Similar documents
PACT. PACT Program. Production Assistance for Cellular Therapies

Educational Web Seminar Ask the Experts

Presentation Outline

IND - Cell Therapy. Robert W. Lindblad, MD, FACEP. Where Did you Hear

Andrew Finnerty General Manager - CCMI

NIH-RAID: A ROADMAP Program


A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas

Taking CAR T-Cells From The Research Laboratory To The GMP Facility

Stem Cell Research: Identifying emerging high priority policy issues

Stem Cells, Regenerative Medicine and cgmp (GTP)

The Cell and Gene Therapy Catapult UK clinical trials database

Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products A Workshop

Current Japanese Regulation for Cell Therapy and NCC strategy

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will

The Cell and Gene Therapy Catapult UK clinical trials database

Supplies and Reagents

NHLBI Gene Therapy Resources

25, :00 12: :00 PM ET 1:00 PM ET

FDA Oversight of Gene Therapy

Advancing Manufacturing for Advanced Therapies

Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre

Cellular and Gene Therapy Products - CBER Update

OUR MISSION OUR EXPERTISE OUR SERVICES

Comparative Oncology Program

CMC Considerations for Stem Cell-based. Donald W. Fink, Jr., Ph.D.

Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

University of California Center for Accelerated Innovation

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA

Nanotechnology and Advanced Materials for more effective Healthcare

Supplies and Reagents

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Cell and gene therapy: scaling up and moving to mass production

Mesenchymal Stromal Cells Large-scale Culture

Stem Cell Research From Bench to Bedside

401 N. Washington Street, Suite 700, Rockville, MD Phone: Fax:

Stem Cells: Introduction and Prospects in Regenerative Medicine.

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

CBER Regulatory Updates: Initiatives for Product Review and Licensure

SCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]

From Bench To Clinic : a personal journey Career Research Advancement Focused Training

Regulatory Perspectives of Japan

MSc in Transfusion and Transplantation Sciences

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

Stem Cells Canadian Perspective

Concept of Integrated Research Platforms

Current SCID Gene Transfer Experience

Related Donor Informed Consent to Participate in Research

Sharing Data: Recovering Registry Addict

RFP # C REQUEST FOR PROPOSAL. Acute Graft versus Host Disease Plasma Biomarker Analysis in Baseline and Post-Treatment Patient Samples

ISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development

Summary of Accomplishments

Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018

Navigating the Manufacturing Process and Assuring the Quality of Regenerative Medicine Therapies A Workshop

RESPONSE TO RFP - Title Page

Topics Covered. FDA s Role in Expediting the Development of Novel Medical Products. How a Regulatory Agency Comes into Existence 3/5/2018

February 15, Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions

Clinical Trials Infrastructure Workshop # 3

Bone Marrow Failure Research Program

Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan

Technology Development Funding Program Round 3

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.

Regulations of Biologics in Taiwan

The NYSCF Research Institute

Cardiac Safety Research Consortium Annual Meeting. Future Areas of Focus & Opportunities 18 October 2016

Pluristem Issues Letter to Shareholders

Regulation of advanced blood cell therapies

Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013

Cell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction

Stem Cell Uses and FDA Regulation

Research Xchange Forum 2018

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD

Cancer Research. Peptide Innovations in. Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics

Greenwood Genetic Center

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value

Expanded Access and the Individual Patient IND

Senior Regulatory Affairs Executive AREAS OF EXPERTISE

REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS

Regulatory Pathways for Rare Diseases

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

Updating International Ethics Guidelines for Stem Cell Research

Cell Therapy Liaison Meeting, June 16, 2006

The Role of Adult Stem Cells in Personalized and Regenerative Medicine

Specifications. February 19, 2015, TOKYO, JAPAN. Takao Hayakawa, Ph.D. Director, Pharmaceutical Research and Technology Institute, Kindai University

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

FDA Regulatory Updates: Related to Cancer Immunotherapy

The NIH Peer Review System

Inspections, Compliance, Enforcement, and Criminal Investigations

SMEs in IMI2 Calls for Proposals

HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE

Lead the way. Molecular Imaging. GE Healthcare. imagination at work

Transcription:

Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs) from 3 to 5 Mission Provide assistance for cellular therapy translational research and the manufacture of cellular therapy products 2

PACT Organizational Structure National Heart Lung and Blood Institute Steering Committee External Review Panel 5 Cell Processing Facilities Coordinating Center (The EMMES Corporation) Baylor College of Medicine CAGT City of Hope CATD CHCT Boston University of Minnesota MCT University of Wisconsin Madison WCBF 3 NHLBI Expectations Continue to advance cellular therapy research in the areas of heart, lung and blood cellular therapy research Provide consulting, manufacturing, preclinical study and early phase clinical trial study design, and administrative and regulatory expertise Foster partnership of transfusion medicine and hematology with cell based therapy Collaborate with other NIH groups (CTSA) to streamline clinical and translational research Provide educational leadership in the field of cell therapy 4

NHLBI Expectations Additional Services Support for proof of principle animal and early translational research Provide centralized services (i.e. functional assays) 5 Expanded Interest Support for translational work All translational work will be evaluated Specific support for GMP translational work not funded through standard grant mechanisms 6

Applications Scope: Products and Services Products that aid in the repair and regeneration of damaged/diseased tissues, organs, and biologic systems Products of programmatic interest to the Institute and associated with a funded clinical study Preclinical studies including basic and translational (animal models) work 7 Applications Sample NHLBI Scope: Cardiac repair and disease Lung repair and disease Complications of malignancy treatment (GVHD) Hematologic disease outside of primary treatment for malignancy For more information on criteria for evaluation of PACT product requests visit www.pactgroup.net 8

Today s s Discussion Facilities Translational and Clinical projects that serve as examples of what PACT will support EMMES Application Process 9 Contact Information Traci Heath Mondoro and Lisbeth Welniak Phone: 301 435 0065 Email: mondorot@nhlbi.nih.gov welniakla@nhlbi.nih.gov 10

May 4, 2010 PACT Webcast Overview Production Assistance for Cellular Therapies (PACT) is an NHLBI-sponsored program. PACT is offering this web seminar to introduce the program to the cell therapy community and investigators potentially in need of cell products and cell therapy related services. Web Seminar Description: The purpose of the webcast is to describe the mission and goals of the PACT program and to answer participants questions about the program s goals, the application process and criteria, and the details surrounding PACT product manufacturing assistance. Intended Audience: Clinical investigators, Scientists, Researchers, and Technologists specializing in cell therapy I. NHLBI Presentation: Overview of the PACT program. Scope criteria used for accepting applications. Slide set available on the PACT website at www.pactgroup.net. The renewed PACT program continues to advance cellular therapy research in the area of immune based cell therapeutics, regenerative medicine and other treatments for diseases that do not currently have effective therapies. The program s scope is expansive supporting all translational research related to the development of novel cellular therapeutics including those that fall outside NHLBI scope. Requests for clinical product manufacturing, however, are restricted to those that fall within the programmatic interests of the NHLBI. PACT Facility Core Competencies Quality and Compliance Operations/Materials Management Control of Critical Systems Program Budgets/Forecasts/Cost Accounting Business Plan Development/Project and Resources Management Equipment Management Document Change Control Process Development, Qualification, Validation Regulatory Affairs RAC, Pre-IND, IND support II. PACT Cell Processing Facility (CPF) Speakers: To illustrate types of preclinical and clinical projects, a speaker from each facility will provide examples of currently ongoing work at their Facility: Ann Leen, PhD Baylor College of Medicine Center for Cell and Gene Therapy Larry Couture, PhD City of Hope, Center for Applied Technology Development Myriam Armant, PhD Center for Human Cell Therapy Boston Derek Hei, PhD University of Wisconsin Madison, Waisman Clinical BioManufacturing Facility John Wagner, MD University of Minnesota Molecular and Cellular Therapeutics Facility May Version 1.0 Page 1

May 4, 2010 PACT Webcast Overview A. Ann Leen, PhD - Baylor College of Medicine Center for Cell and Gene Therapy (CAGT) Email: amleen@txccc.org Phone: (832) 824-4690 CAGT Facility Overview Translational Research Laboratories cgmp Manufacturing Facility o Quality Control Laboratory and Quality Assurance GMP Vector Production Facility B. Larry Couture, PhD City of Hope, Center for Applied Technology Development (CATD) Email: lcouture@coh.org Phone: (626) 256-8728 CATD Facility Overview Office of Project Management Office of Technology Licensing Center for Biomedicine and Genetics Office of Regulatory Affairs Office of Quality Systems CATD Active Projects (translational) H1 hesc Master Cell bank Establishment of Cardiomyocyte Differentiation Process C. Myriam Armant, PhD Center for Human Cell Therapy (CHCT) Boston Email: info@chct.org Phone: (617) 919-2390 CHCT Facility Overview Translational Laboratory o Immune Disease Institute o Programs in Cellular and Molecular Medicine at Children s Hospital Boston Cell Manipulation Core Facility o Dana Farber Cancer Institute CHCT Active Projects (translational) Myocardial Regeneration using Cardiac Stem Cells Harvested from Right Atrial Appendages in Patients with Ischemic Cardiomyopathy. May Version 1.0 Page 2

May 4, 2010 PACT Webcast Overview D. Derek Hei, PhD University of Wisconsin Madison, Waisman Clinical BioManufacturing Facility (WCBF) Email: hei@waisman.wisc.edu Phone: (608) 263-5821 WCBF Facility Overview Waisman Clinical BioManufacturing Facility Clinical Stem Cell Collection and Processing Lab Pre-Clinical Animal Studies Core Regulatory Affairs Core WCBF Active Projects (translational) Human ES Cell Banks Mesenchymal Stem Cell Banks E. John Wagner, MD University of Minnesota Molecular and Cellular Therapeutics (MCT) Email: wagne002@umn.edu Phone: (612) 626-2961 MCT Facility Overview Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Fairview Cancer Center/Regenerative Medicine Translational Laboratory Pancreatic Islet Transplant Program Active Pharmaceutical Ingredient Synthesis/Biotherapeutic Protein Production Facility MCT Active Projects (translational) UCB T Regulatory Cells to Prevent Acute Graft-versus-Host Disease III. EMMES Corporation (PACT Coordinating Center) Presentation: Overview of the PACT online application process. Access the online application using www.pactgroup.net Slide set available on the PACT website at www.pactgroup.net A Preliminary application is initially submitted and reviewed by the PACT Steering Committee (SC) to determine if the proposal is compatible with the NHLBI mission and objectives of supporting heast, lung and blood cellular therapy research. If appropriate, the applicant will be invited to submit a full application. The full application is needed to obtain the additional information required by the Steering Committee (SC) to evaluate the request, and if approved, to assign the work to the appropriate Cell Processing Facility (CPF). After verification that all requested information is included, the full application and associated materials will be provided to the PACT SC for review. The Criteria for Evaluation and Product Requests document is available on the PACT web site (www.pactgroup.net) to assist you completing your application. May Version 1.0 Page 3

APPLICATION PROCESS Robert Lindblad, MD EMMES Corporation Rockville, Maryland PACT Application Process Web based Preliminary Application Concept Review by Steering Committee Full Application Invited Technical Liaison Assigned Web based Full Application Peer Reviewed & SC Vote Budget, Contract & Timeline 2 1

Full Application Content Translational or Clinical SOPs and validation information Any manufacturing financial support Clinical trial financial support Details of amount of product required Clinical protocol and safety monitoring plan IND/regulatory status Proposed timeline and budget 3 Steering Committee Review Criteria Scientific merit & relevance to NHLBI Level of translation work Clinical trial design Funding Regulatory status Availability of expertise at PACT Capacity at PACT 4 2

Next Steps Budget Contract Contract negotiations with designated facility Draft contract developed Intellectual property and/or indemnification Timeline Development of production task order Scheduling of manufacturing tasks Scheduling of production 5 Website www.pactgroup.net Application process information Education Initiatives FAQ and updates Links to PACT facilities, regulatory references & other resources 6 3

Contact Information Robert Lindblad, Jamie Winestone or Debbie Wood Phone: 301 251 1161 Email: pactinfo@pactgroup.net 7 4